You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Valiant Thoracic Stent Graft with the Captivia Delivery System
for Thoracic Endovascular Aortic Repair (TEVAR)
The Valiant™ Captivia™ stent graft system is designed to treat all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), type B aortic dissection (TBAD), intramural hematoma (IMH), penetrating atherosclerotic (PAU), and blunt thoracic aortic injury (BTAI).
Valiant™ Captivia™ thoracic stent graft system maintains vessel wall apposition and fixation, regardless of angulation and oversizing.1 Clinically supported by low type Ia endoleak rate (0% at 5 years).2 The stent graft system has over a decade of worldwide experience and has been chosen for over 150,000† patients worldwide. It has five years of clinical data across all descending thoracic aortic pathologies.2–4
Case image courtesy of Dr. Roy M. Fujitani, M.D.
Results
The Valiant™ Captivia™ stent graft system remained apposed to the aortic wall at each increment of neck angulation and degree of oversizing in a simulated environment.
For the other stent grafts tested, lack of device wall apposition was observed between the proximal anchorage segment and the inferior aortic wall.
Angular flexibility and radial strength give the Valiant™ Captivia™ stent graft conformability and optimal seal1
† 10–19% device oversizing.
Risks associated with TEVAR procedures may include rupture, conversion to open repair, or secondary procedures.
Product tested | Proximal apposition at different landing zone angulation | Body apposition at different landing zone angulation |
---|---|---|
Medtronic Valiant™ Captivia™ system | No lack of apposition (remained apposed) | No lack of apposition (remained apposed) |
A | Lack of apposition above 120º | No lack of apposition (remained apposed) |
B | No lack of apposition (remained apposed) | Lack of apposition above 110º |
C | Lack of apposition above 110º | No lack of apposition (remained apposed) |
Test data not indicative of clinical performance.
How does Valiant™ Captivia™ system maintain a continuous seal in a dynamic environment?
Animation: Valiant Captivia features and benefits - (01:49)
Valiant Captivia establishes and maintains a continuous seal thanks to peak-to-valley design and complete wall apposition. UC202217002EE
More information (see more)
Less information (see less)
Slow, controlled deployment for precise placement
Quick deployment option, if desired
Tip capture release
Clinician experiences with Valiant™ Captivia™ video - (03:46)
Watch this video to hear leading clinicians discuss why they choose the Valiant™ Captivia™ stent graft system for their patients.
More information (see more)
Less information (see less)
Dr. Frank Arko accuracy video - (03:15)
See how the three-step Captivia™ delivery system enables simple graft adjustment and precise placement within the thoracic aorta.
More information (see more)
Less information (see less)
Dr. Jean Panneton conformability video - (03:41)
Watch this video and hear Dr. Panneton discuss how Valiant™ Captivia™ is highly flexible and conformable due to its sinusoidal shape, super‑elastic nitinol springs, and lack of a longitudinal bar.
More information (see more)
Less information (see less)
Dr. Hitoshi Matsuda dissection video - (02:50)
Watch this video and hear Dr. Matsuda review a type B aortic dissection case he treated with TEVAR, which provides a minimally invasive alternative to open surgical repair.
More information (see more)
Less information (see less)
The Valiant™ thoracic stent graft with the Captivia™ delivery system is indicated for the endovascular repair of all lesions of the descending thoracic aorta (DTA) in patients having the appropriate anatomy, including:
Find this technical manual in the Medtronic Manual Library, in the product labeling supplied with each device, or by calling 877-526-7890.
Use this tool to plan case specifics such as sizing and placement.
194KB
See model specs including stent graft lengths, diameters, tapers, and crossing profiles.
Choose from a complete portfolio of market-leading aortic vascular therapies to treat aneurysm disease.
Find additional information along with a variety of educational resources and tools.
† Data on file. Internal global finance report, total Valiant™ Captivia™ cases.
1. Canaud L, Cathala P, Joyeux F, Branchereau P, Marty-Ané C, Alric P. Improvement in conformability of the latest generation of thoracic stent grafts. J Vasc Surg. 2013;57(4):1084–1089. doi: 10.1016/j.jvs.2012.09.019
2. Conrad MF, Tuchek J, Freezor R, Bavaria J, White R, Fairman R. Results of the VALOR II trial of the Medtronic Valiant thoracic stent graft. J Vasc Surg. 2017;66(2):335–342. doi: 10.1016/j.jvs.2016.12.136.
3. Bavaria JE, Brinkman WT, Hughes GC, et al. Five-year outcomes of endovascular repair of complicated acute type B aortic dissections. J Thorac Cardiovas Surg. 2022;163(2):539–548.e2. doi: 10.1016/j.jtcvs.2020.03.162.
4. Patal HJ, Azizzadeh A, Matsumoto AH, et al. Five-year outcomes from the United States pivotal trial of Valiant Captivia stent graft for blunt aortic injury. Ann Thorac Surg. 2020;110(3):815–820. doi: 10.1016/j.athoracsur.2019.12.028.